Why Collegium Pharmaceutical Shares Are Tumbling 12.9% Today Wed, 22 Nov 2017 21:18:00 +0000 The FDA is working on ways to encourage the development of abuse-deterrent opioid pain relievers, and that's potentially bad news for this tiny biotech.
Collegium to Present at the 29th Annual Piper Jaffray Healthcare Conference Wed, 22 Nov 2017 13:42:34 +0000 CANTON, Mass., Nov. 22, 2017-- Collegium Pharmaceutical, Inc. today announced that senior management will participate in a fireside chat at the 29 th Annual Piper Jaffray Healthcare Conference at 2:30pm ...
Collegium Pharmaceutical, Inc. – Value Analysis (NASDAQ:COLL) : November 13, 2017 Mon, 13 Nov 2017 18:56:57 +0000 Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Collegium Pharmaceutical, Inc. a score of 29. Our analysis is based on comparing Collegium Pharmaceutical, Inc. with the following peers – Aoxing Pharmaceutical Company, Inc., Horizon Pharma plc, Agile Therapeutics, Inc. and Apricus Biosciences, Inc. (AOXG-US, HZNP-US, AGRX-US and APRI-US). Investment Outlook Collegium Pharmaceutical, Inc. has a ... Read more
(Read more...)
Collegium Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : COLL-US : November 10, 2017 Fri, 10 Nov 2017 12:17:34 +0000 Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Collegium Pharmaceutical, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more
(Read more...)
Collegium Pharmaceutical posts 3Q loss Wed, 08 Nov 2017 22:25:36 +0000 On a per-share basis, the Canton, Massachusetts-based company said it had a loss of 45 cents. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
Collegium Reports Third Quarter Financial Results and Provides Corporate Update Wed, 08 Nov 2017 21:01:00 +0000 Xtampza ® ER prescriptions grow by 49% in the third quarter FDA Approval of sNDA, including Comparative OxyContin Data Strong balance sheet provides cash runway into mid-2019 Conference call scheduled ...
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.